Journal of Ophthalmic and Vision Research
ISSN: 2008-322X
The latest research in clinical ophthalmology and vision science
Neuro-ophthalmic Manifestations of Giant Cell Arteritis: A Review
Published date: Jun 24 2025
Journal Title: Journal of Ophthalmic and Vision Research
Issue title: Volume 20 - 2025
Pages: 1 - 13
Authors:
Abstract:
Giant cell arteritis (GCA) is the most common vasculitis of large and medium vessels affecting adults over the age of 50. Due to its acute ischemic damage through a systemic inflammatory process, GCA is a medical emergency with the risk of permanent vision loss. Therefore, early intervention is critical. Patients often present with well-documented systemic manifestations such as jaw claudication, headache, scalp tenderness, and fatigue. These patients are usually subject to blood tests for inflammatory markers and temporal artery biopsy. However, clinical manifestations vary considerably and may masquerade as neuro-ophthalmic manifestations that are not pathognomonic of GCA. We conducted a review to discuss documented neuroophthalmic manifestations and provide insight into the rare presentations to help avoid pitfalls in its diagnosis. Findings from the included articles were sorted into afferent and efferent neuroophthalmic manifestations. According to our literature review, the main afferent manifestations documented are ischemic optic neuropathy, retinal artery occlusion, choroidal infarction, ocular ischemic syndrome, orbital inflammatory syndrome, and strokes causing visual field loss. The efferent manifestations include cranial neuropathy (3rd, 4th, and 6th), extraocular muscle ischemia, and internuclear ophthalmoplegia. Other rare causes are tonic pupil from ciliary ganglion involvement, uveitis, and encephalopathy. If GCA is suspected, in addition to inquiring about systemic symptoms and doing a complete neuro-ophthalmic exam, these patients should be sent for inflammatory serological markers, as well as temporal artery biopsy (TAB). If clinical suspicion remains high, high-dose steroids should be started immediately.
Keywords: Giant Cell Arteritis, Neuro-Ophthalmology, Vision Disorders, Visual Symptoms
References:
1. Bengtsson BA, Malmvall BE. The epidemiology of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. Incidences of different clinical presentations and eye complications. Arthritis Rheum 1981;24:899– 904.
2. Samson M, Corbera-Bellalta M, Audia S, Planas-Rigol E, Martin L, Cid MC, et al. Recent advances in our understanding of giant cell arteritis pathogenesis. Autoimmun Rev 2017;16:833–844.
3. Fein AS, Ko MW. Neuro-ophthalmologic complications of giant cell arteritis: Diagnosis and treatment. Semin Neurol 2019;39:673–681.
4. Lazarewicz K, Watson P. Giant cell arteritis. BMJ 2019;365:l1964.
5. Raizada K, Margolin E. Non-arteritic anterior ischemic optic neuropathy. StatPearls; 2023. http://www.ncbi.nlm.nih.gov/books/NBK559045/
6. Hayreh SS. Ischemic optic neuropathy. Prog Retin Eye Res 2009;28:34–62.
7. Hattenhauer MG, Leavitt JA, Hodge DO, Grill R, Gray DT. Incidence of nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 1997;123:103–107.
8. Hayreh SS, Podhajsky PA, Zimmerman B. Ocular manifestations of giant cell arteritis. Am J Ophthalmol 1998;125:509–520.
9. Danesh-Meyer HV, Savino PJ, Sergott RC. The prevalence of cupping in end-stage arteritic and nonarteritic anterior ischemic optic neuropathy. Ophthalmology 2001;108:593–598.
10. Danesh-Meyer HV, Savino PJ, Sergott RC. The prevalence of cupping in end-stage arteritic and nonarteritic anterior ischemic optic neuropathy. Ophthalmology 2001;108:593–598.
11. Hayreh SS, Zimmerman MB. Incipient nonarteritic anterior ischemic optic neuropathy. Ophthalmology 2007;114:1763–1772.
12. Characteristics of patients with nonarteritic anterior ischemic optic neuropathy eligible for the Ischemic Optic Neuropathy Decompression Trial. Arch Ophthalmol Chic Ill 1960 1996;114:1366–1374.
13. Beck RW, Servais GE, Hayreh SS. Anterior ischemic optic neuropathy. IX. Cup-to-disc ratio and its role in pathogenesis. Ophthalmology 1987;94:1503–1508.
14. Newman NJ. The ischemic optic neuropathy decompression trial. Arch Ophthalmol 2007;125:1568– 1570.
15. Hayreh SS. Central retinal artery occlusion. Indian J Ophthalmol 2018;66:1684–1694.
16. Kιyat P, Değirmenci C, Nalçacι S, Afrashi F, Akkιn C. Paracentral acute middle maculopathy. Turk J Ophthalmol 2020;50:193–196.
17. Mairot K, Sené T, Lecler A, Philibert M, Clavel G, Hemmendinger A, et al. Paracentral acute middle maculopathy in giant cell arteritis. Retina 2022;42:476– 484.
18. Dammacco R, Alessio G, Giancipoli E, Leone P, Cirulli A, Resta L, et al. Giant cell arteritis: The experience of two collaborative referral centers and an overview of disease pathogenesis and therapeutic advancements. Clin Ophthalmol 2020;14:775–793.
19. Kopsachilis N, Pefkianaki M, Marinescu A, Sivaprasad S. Giant cell arteritis presenting as choroidal infarction. Case Rep Ophthalmol Med 2013;2013:597398.
20. Özdal PÇ, Tugal-Tutkun I. Choroidal involvement in systemic vasculitis: A systematic review. J Ophthalmic Inflamm Infect 2022;12:14.
21. Sood G, Siddik AB. Ocular ischemic syndrome. StatPearls; 2023. http://www.ncbi.nlm.nih.gov/books/NBK560715/
22. Brown GC, Magargal LE. The ocular ischemic syndrome. Clinical, fluorescein angiographic and carotid angiographic features. Int Ophthalmol 1988;11:239–251.
23. Gupta S, Sethi P, Duvesh R, Sethi HS, Naik M, Rai HK. Optic perineuritis. BMJ Open Ophthalmol 2021;6:e000745.
24. Bergman O, Andersson T, Zetterberg M. Optic perineuritis: A retrospective case series. Int Med Case Rep J 2017;2017:181–188.
25. Pappolla A, Silveira F, Norscini J, Miquelini L, Patrucco L. Bilateral optic perineuritis as initial presentation of giant cell arteritis. Neurologist 2019;24:26–28.
26. Purvin V, Kawasaki A, Jacobson DM. Optic perineuritis: Clinical and radiographic features. Arch Ophthalmol 2001;119:1299–1306.
27. Bajko Z, Balasa R, Maier S, Motataianu A, Barcutean L, Andone S, et al. Stroke secondary to giant-cell arteritis: A literature review. Exp Ther Med 2021;22:876.
28. Ross AG, Jivraj I, Rodriguez G, Pistilli M, Chen JJ, Sergott RC, et al. Retrospective, multicenter comparison of the clinical presentation of patients presenting with diplopia from giant cell arteritis vs other causes. J Neuroophthalmol 2019;39:8–13.
29. Vodopivec I, Rizzo JF 3rd. Ophthalmic manifestations of giant cell arteritis. Rheumatology 2018;57:ii63–ii72.
30. Thurtell MJ, Longmuir RA. Third nerve palsy as the initial manifestation of giant cell arteritis. J Neuroophthalmol 2014;34:243–245.
31. Khanam S, Sood G. Trochlear nerve palsy. StatPearls; 2023. http://www.ncbi.nlm.nih.gov/books/NBK565850/
32. Lunagariya A, Rupareliya C, Bollu PC, Mahuwala Z. Temporal arteritis presenting as an isolated bilateral abducens nerve palsy: A rare case of a 65-year-old male. Cureus; 2018. https://www.cureus.com/articles/12439- temporal-arteritis-presenting-as-an-isolated-bilateralabducens- nerve-palsy-a-rare-case-of-a-65-year-oldmale
33. Ahmad I, Zaman M. Bilateral internuclear ophthalmoplegia: An initial presenting sign of giant cell arteritis. J Am Geriatr Soc 1999;47:734–736.
34. Jensen GL, Al Othman B, Kini A, Prospero Ponce CM, Lee AG. Internuclear ophthalmoplegia as the presenting sign of giant cell arteritis. J Neuroophthalmol 2020;40:92– 94.
35. Currie J, Lessell S. Tonic pupil with giant cell arteritis. Br J Ophthalmol 1984;68:135–138.
36. Prasad S, Baccon J, Galetta SL. Mydriatic pupil in giant cell arteritis. J Neurol Sci 2009;284:196–197.
37. Pauls M, Singh M, Martin P. An unusual case of giant cell arteritis. Pract Neurol 2021;21:228–230.
38. Falsetti P, Acciai C, Conticini E, Cantarini L, Frediani B. Atypical posterior reversible encephalopathy syndrome (PRES) in a patient with polymyalgia rheumatica and giant cell arteritis. Curr Health Sci J 2021;47:306–309.
39. Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002;347:261–271.
40. Bandini F, Benedetti L, Ceppa P, Corallo G. Uveitis as a presenting sign of giant cell arteritis. J Neuroophthalmol 2005;25:247–248.
41. Mercier C, Scheiber M, Lez ML, Erra B, Bigot A, Diot E. Anterior uveitis with negative work-up: Giant cell arteritis remains the pet peeve. Curr Rheumatol Rev 2020;16:165–168.
42. Peral-Cagigal B, Pérez-Villar Á, Redondo-González LM, García-Sierra C, Morante-Silva M, Madrigal-Rubiales B, et al. Temporal headache and jaw claudication may be the key for the diagnosis of giant cell arteritis. Med Oral Patol Oral Cir Bucal 2018;23:e290–e294.
43. Ponte C, Martins-Martinho J, Luqmani RA. Diagnosis of giant cell arteritis. Rheumatology 2020;59:iii5–iii16.
44. Hayreh SS, Zimmerman B. Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy. Ophthalmology 2003;110:1204– 1215.
45. Hayreh SS, Podhajsky PA, Zimmerman B. Occult giant cell arteritis: Ocular manifestations. Am J Ophthalmol 1998;125:521–526.
46. Rahman W, Rahman FZ. Giant cell (temporal) arteritis: An overview and update. Surv Ophthalmol 2005;50:415– 428.
47. Costello F, Zimmerman MB, Podhajsky PA, Hayreh SS. Role of thrombocytosis in diagnosis of giant cell arteritis and differentiation of arteritic from non-arteritic anterior ischemic optic neuropathy. Eur J Ophthalmol 2004;14:245–257.
48. Bowling K, Rait J, Atkinson J, Srinivas G. Temporal artery biopsy in the diagnosis of giant cell arteritis: Does the end justify the means? Ann Med Surg 2017;20:1–5.
49. Taylor-Gjevre R, Vo M, Shukla D, Resch L. Temporal artery biopsy for giant cell arteritis. J Rheumatol 2005;32:1279–1282.
50. Agostino A, Farmer J, Blanco P, Veinot JP, Nair V. Efficacy of bilateral temporal artery biopsies and sectioning of the entire block of tissue for the diagnosis of temporal arteritis. Cardiovasc Pathol 2022;59:107425.
51. Ponte C, Rodrigues AF, O’Neill L, Luqmani RA. Giant cell arteritis: Current treatment and management. World J Clin Cases 2015;3:484–494.
52. Maz M, Chung SA, Abril A, Langford CA, Gorelik M, Guyatt G, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis Rheumatol 2021;73:1349–1365.
53. Aiello PD, Trautmann JC, McPhee TJ, Kunselman AR, Hunder GG. Visual prognosis in giant cell arteritis. Ophthalmology 1993;100:550–555.
54. Mahr AD, Jover JA, Spiera RF, Hernández-García C, Fernández-Gutiérrez B, Lavalley MP, et al. Adjunctive methotrexate for treatment of giant cell arteritis: An individual patient data meta-analysis. Arthritis Rheum 2007;56:2789–2797.
55. Koster MJ, Yeruva K, Crowson CS, Muratore F, Labarca C, Warrington KJ. Efficacy of methotrexate in real-world management of giant cell arteritis: A case-control study. J Rheumatol 2019;46:501–508.
56. Oliveira F, Butendieck RR, Ginsburg WW, Parikh K, Abril A. Tocilizumab, an effective treatment for relapsing giant cell arteritis. Clin Exp Rheumatol 2014;32:S76–S78.
57. Christidis D, Jain S, Das Gupta B. Successful use of tocilizumab in polymyalgic onset biopsy positive GCA with large vessel involvement. BMJ Case Rep 2011;2011:bcr0420114135.
58. Beyer C, Axmann R, Sahinbegovic E, Distler JH, Manger B, Schett G, et al. Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis. Ann Rheum Dis 2011;70:1874–1875.
59. Unizony S, Arias-Urdaneta L, Miloslavsky E, Arvikar S, Khosroshahi A, Keroack B, et al. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res 2012;64:1720–1729.
60. Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med 2017;377:317–328.
